メニュー戻る Copy of History

A Look Back at the 2017 EuroMeeting

DIA Europe 2018 | 2017 EuroMeeting Audience

The DIA 29th Annual EuroMeeting in Glasgow brought stakeholders together to collaborate on when, where and how innovation leads to advances in health care product development.

Conversations at the 2017 EuroMeeting included:

Global Regulatory Convergence

“No one has ever systematically looked at our [EMA and FDA] differences, what is the source of it? … We are starting to see more of an uptake of joint scientific advice. Particularly on areas where the resources are scarce, the patients are few. Our job is to make simple for the companies as well as for the regulatory agencies, as we do have different procedures that can be a challenge”

Value and Access

“There is an issue about sustainability of healthcare - are we able also in the future pay for these medicines and how much are we willing to pay for them? DIA plays a role in bringing different parties together to the table. We have new ways in dealing with the evolving insights how to treat the patients. The need of having different parties together is really growing.”
- Ri de Ridder, Director General, Belgian National Insurance, RIVIZ-INAMI

Trends in Clinical Operations

"The future entails:

Study protocols to be designed evidence-based when using Electronic Health Records (EHRs)
EHRs to facilitate access to patients for research
Registries are a way to bring patients closer to research
Social networks for specific diseases may replace more complex registries”

- Peter Schueler, Senior Vice President, Drug Development Services, CNS, for ICON plc

Patient Engagement

“These patient insights help us improve the therapeutic options and delivery technologies, adherence tools and patient-reported outcomes AND the clinical trials experience, just to name a few of the important consequences.”
- Susan Forda, Vice President of International Regulatory Affairs, Eli Lilly & Company Limited

Addressing Industry Concerns

Audience Poll Question: Are we as Europeans getting the innovation that society wants and needs? 57%, a majority, responded “No”
To tackle those responses a panel of key stakeholders in the European medicines system shared their views on how to innovate, engage and evolve in a regulatory setting which ensures that innovations reach patients.